Skip to main content
SpringerLink
Log in

Klinik — orale Medikation

  • Chapter
Neuro-Psychopharmaka Ein Therapie-Handbuch

  • 90 Accesses

Zusammenfassung

Da die Ursache des degenerativen Prozesses beim M. Parkinson noch unbekannt ist, ist eine kausale Therapie nicht mÖglich. Primäres Ziel der symptomatisch orientierten medikamentÖsen Therapie ist somit der Ausgleich des Striatalen Dopamindefizits entweder durch Substitution mit L-Dopa oder durch Verbesserung der dopaminergen Transmission. Von besonderer Bedeutung ist dabei die Stimulation postsynaptischer D1- und D2-Rezeptoren durch Dopaminagonisten.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 64.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  • Ahlskog JE, Muenter MD (1988a) Pergolide: long-term use in Parkinson’s disease. Mayo Clin Proc 63: 979–987

    Article  PubMed  CAS  Google Scholar 

  • Ahlskog JE, Muenter MD (1988b) Treatment of Parkinson’s disease with pergolide: a double-blind study. Mayo Clin Proc 63: 969–978

    Article  PubMed  CAS  Google Scholar 

  • Ahlskog JE, Muenter MD, Maraganore DM, Matsumoto JY, Lieberman A, Wright KF, Wheeler K (1994) Fluctuating Parkinson’s disease. Treatment with the long-acting dopamine agonist cabergoline. Arch Neurol 51: 1236–1241

    Article  PubMed  CAS  Google Scholar 

  • Bergamasco B, Benna P, Scarzella L (1990) Long-term bromocriptine treatment of de novo patients with Parkinson’s disease. A seven-year follow-up. Acta Neurol Scand 81: 383–387

    Article  PubMed  CAS  Google Scholar 

  • Bonnet AM, Serre I, Marconi R, Agid Y, Dubois B (1995) A combined levodopa test as a useful method evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine. Mov Disord 10: 668–671

    Article  PubMed  CAS  Google Scholar 

  • Calne DB, Teychenne PF, Claveria LE et al. (1974) Bromocriptine in parkinsonism. Br Med J 4: 442–444

    Article  PubMed  CAS  Google Scholar 

  • Calne DB, Teychenne PF, Leigh PN (1974) Treatment of Parkinsonism with bromocriptine. Lancet ii: 1355–1358

    Article  Google Scholar 

  • Calne DB, Plotkin CH, Williams AC, Nutt JG, Neophytides A, Teychenne PF (1978) Longterm treatment of Parkinsonism with bromocriptine. Lancet i: 735–737

    Article  Google Scholar 

  • Canonico PL (1993) Relative bioequivalence of three oral forms of daverium: capsules, tablets, oral drops. Study with a single dose of 20 mg in male and female volunteers (unpublished)

    Google Scholar 

  • Dupont E, Boas J, Mikkelsen B, Wermuth L, Worm-Petersen J (1996) The levodopa dose-sparing capacity of pergolide compared with that of bromocriptine. Eur J Neurol 3[Suppl 1]: 9–12

    Google Scholar 

  • Emskotter T, Lachenmayer L, Heidenreich C (1989) The problems of L-dopa therapy in the course of Parkinson syndrome. Fortschr Neurol Psychiatr 57: 192–197

    Article  PubMed  CAS  Google Scholar 

  • Factor SA, Weiner WJ (1993) Early combination therapy with bromocriptine and levodopa in Parkinson’s disease. Mov Disord 8: 257–262

    Article  PubMed  CAS  Google Scholar 

  • Fischer PA, Przuntek H, Majer M, Welzel D (1984) Combined treatment of the early stages of Parkinson’s syndrome with bromocriptine and levodopa. The results of a multicenter study. Dtsch Med Wochenschr 109: 1279–1283

    Article  PubMed  CAS  Google Scholar 

  • Grimes JD, Kind DB, Kofman OS, Molina-Negro P, Wilson AF, Bouchard S (1984) Bromocriptine in the management of end of dose deterioration in Parkinson’s disease. Can J Neurol Sci 11: 452–456

    PubMed  CAS  Google Scholar 

  • Guttman M, Frcpc, AND the International Pramipexole-Bromocriptine Study Group (1997) Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease. Neurology 49: 1060–1065

    Article  PubMed  CAS  Google Scholar 

  • Heinz A, Suchy I, Klewin I, Kuhn W, Klotz P, Przuntek H (1992) Long-term observation of chronic subcutaneous administration of lisu-ride in the treatment of motor fluctuations in Parkinson’s disease. J Neural Transm [PD-Sect] 4: 291–301

    Article  CAS  Google Scholar 

  • Hely MA, Morris JGL, Reid WGJ, O’Sullivan DJ, Williamson PM (1994) The Sydney Multicentre Study of Parkinson’s disease: a randomized, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 57: 903–910

    Article  PubMed  CAS  Google Scholar 

  • Horowski R, Wachtel H (1976) Direct dopaminergic action of lisuride hydrogenmaleate, an ergot derivative, in mice. Eur J Pharmacol 36: 373–383

    Article  PubMed  CAS  Google Scholar 

  • Horowski R, Obeso JA (1990) Lisuride: a direct dopamine agonist in the treatment of Parkinson’s disease. In: Koller WC, Paulson G (eds) Therapy in Parkinson’s disease. Marcel Dekker, New York, pp 269–309

    Google Scholar 

  • Horstink MW, Berger HJ, van de Vlasakker CJ (1995) Cabergoline in Parkinson’s disease. Neurology 45: 1233–1234

    Article  PubMed  CAS  Google Scholar 

  • Hutton JT, Koller WC, Ahlskog JE, Pahwa R, Hurtig HI et al. (1996) Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson’s disease. Neurology 46: 1062–1065

    Article  PubMed  CAS  Google Scholar 

  • Jackson DM, Jenkins OF, Ross SB (1988) The motor effects of bromocriptine — a review. Psychopharmacology Berl 95: 433–446

    Article  PubMed  CAS  Google Scholar 

  • Jörg J, Schneider I (1988) Clinical aspects and pathogenesis of the „on-off“ phenomenon in Parkinson syndrome. Fortschr Neurol Psychiatr 56: 22–34

    Article  PubMed  Google Scholar 

  • Korcyn AD, Brooks D, Brunt ER, Poewe WH, Rascol O et al. (1998) Ropinirol versus bromocriptine in the treatment of early Parkinson’s disease: a 6-month interim report of a 3-year study. Mov Disord 13: 46–51

    Article  Google Scholar 

  • Lees AJ (1994) Levodopa substitution: the gold standard. Clin Neuropharmacol 17: 1–6

    Article  Google Scholar 

  • Lees AJ, Stern GM (1983) Sustained bromocriptine therapy in previously untreated patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 44: 1020–1023

    Article  Google Scholar 

  • Lera G, Vaamonde, J Muruzabal, J, Obeso JA (1990) Cabergoline: a long-acting dopamine agonist in Parkinson’s disease. Ann Neurol 28: 593–594

    Article  PubMed  CAS  Google Scholar 

  • Lera G, Vaamonde J, Rodriguez M, Obeso JA (1993) Cabergoline in Parkinson’s disease: long-term follow-up. Neurology 43: 2587–2590

    Article  PubMed  CAS  Google Scholar 

  • Le Witt PA, Ward CD, Larsen TA, et al. (1983) Comparison of pergolide and bromocriptine in parkinsonism. Neurology 33: 1009–1014

    Article  Google Scholar 

  • Lieberman A, Gopinathan G, Neophytides A, Goldstein M (1986) Management of levodopa failure: the use of dopamine agonists. Clin Neuropharmacol 9[Suppl 1]: 9–21

    Google Scholar 

  • Lieberman A, Gopinathan G, Neophytides A, Nelson J, Goldstein M (1990) Dopamine agonists in Parkinson’s disease. In: Stern G (ed) Parkinson’s disease. Chapman Hall, London, pp 509–557

    Google Scholar 

  • Lieberman A, Ranhasky A, Korts D (1997) Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 49: 162–168

    Article  PubMed  CAS  Google Scholar 

  • Luquin MR, Obeso JA, Martinez Lage JM, Tresguerres J, Parada J, Nieuweboer B, Dorow R, Horowski R (1987) Parenteral administration of lisuride in Parkinson’s disease. Adv Neurol 45: 561–568

    PubMed  CAS  Google Scholar 

  • Madeja UD (1992) The dopamine agonist, lisuride, in the therapy of Parkinson disease. Acta Histochem [Suppl] 42: 25–31

    CAS  Google Scholar 

  • Marsden CD (1990) Parkinson’s disease. Lancet 335: 948–952

    Article  PubMed  CAS  Google Scholar 

  • Mear J, Barroche G, de Smet Y, et al. (1984) Pergolide in the treatment of Parkinson’s disease. Neurology 34: 983–986

    Article  PubMed  CAS  Google Scholar 

  • Meneghetti G, Bracco F, Giometto B, Ferla S, Schergna E (1986) Therapeutic effect of lisuride in advanced Parkinson’s disease. Eur Neurol 25: 74–80

    Article  PubMed  CAS  Google Scholar 

  • Mierau J, Schingnitz G (1992) Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. Eur J Pharmacol 215: 161–170

    Article  PubMed  CAS  Google Scholar 

  • Mizuno Y, Kondo T, Narabayashi H (1995) Pergolide in the treatment of Parkinson’s disease. Neurology 45[Suppl 3]: S13–S21

    Article  PubMed  CAS  Google Scholar 

  • Montastruc JL, Rascol O, Rascol A (1988) Bromocriptine versus levodopa in the early treatment of Parkinson’s disease. First results after 2 years. Therapie 43: 461–463

    PubMed  CAS  Google Scholar 

  • Montastruc JL, Rascol O, Rascol A (1989) A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up. J Neurol Neurosurg Psychiatry 52: 773–775

    Article  PubMed  CAS  Google Scholar 

  • Montastruc JL, Rascol O, Senard JM, Rascol A (1994) A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson’s disease: a five year follow up. J Neurol Neurosurg Psychiatry 57: 1034–1038

    Article  PubMed  CAS  Google Scholar 

  • Obeso JA, Grandas F, Herrero MT, Horowski R (1994) The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson’s disease. Eur J Neurosci 6: 889–897

    Article  PubMed  CAS  Google Scholar 

  • Ogawa N, Kanazawa I, Kowa H, Kuno S, Mizuno Y, Tashiro K, Yanagisawa N (1997) Nationwide multicenter prospective study on the long-term effects of bromocriptine in Parkinson’s disease. Eur Neurol 38[Suppl 2]: 37–49

    Article  PubMed  CAS  Google Scholar 

  • Olanow CW, Fahn S, Muenter M, Klawans H, Hurtig H, Stern M, Shoulson I, Kurlan R, Grimes JD, Jankovic J et al. (1994) A multi-center double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson’s disease. Mov Disord 9: 40–47

    Article  PubMed  CAS  Google Scholar 

  • Olanow CW, Hauser RA, Ganger L et al. (1995) The effect of deprenyl and levodopa on the progression of Parkinson’s disease. Ann Neurol 38: 771–777

    Article  PubMed  CAS  Google Scholar 

  • Pahwa R, Koller WC (1995) Dopamine agonists in the treatment of Parkinson’s disease. Cleve Clin J Med 62: 212–217

    PubMed  CAS  Google Scholar 

  • Pezzoli G, Martignoni E, Pacchetti C, Angeleri V, Lamberti P, Muratorio A, Bonuccelli U, de Mari M, Foschi N, Cossutta E et al. (1995) A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson’s disease. Neurology 45: S22–22S27

    Article  Google Scholar 

  • Poewe W (1995) Pergolid. Akt Neurol 22: 71–74

    Article  Google Scholar 

  • Przuntek H, Welzel D, Blumner E, Danielczyk W, Letzel H, Kaiser HJ, Kraus PH, Riederer P, Schwarzmann D, Wolf H et al. (1992a) Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: pra-do-study discontinued. Eur J Clin Pharmacol 43: 357–363

    Article  PubMed  CAS  Google Scholar 

  • Przuntek H, Welzel D, Schwarzmann D, Letzel H, Kraus PH (1992b) Primary combination therapy of early Parkinson’s disease. A long-term comparison between the combined regimen bromo-criptine/levodopa and levodopa monotherapy — first interim report. Eur Neurol 32[Suppl 1]: 36–45

    Article  PubMed  Google Scholar 

  • Przuntek H, Welzel D, Gerlach M, Blummer E, Danielczyk W, Kaiser HJ et al. (1996) Early institution of bromocriptine in Parkinson’s disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study. J Neural Transm 103: 699–715

    Article  PubMed  CAS  Google Scholar 

  • Rascol A, Montastruc JL, Rascol O (1984) Should dopamine agonists be given early or late in the treatment of Parkinson’s disease? Can J Neurol Sci 11: 229–232

    PubMed  CAS  Google Scholar 

  • Rascol OJ (1994) Antiparkinsonian efficacy of ropirinole vs placebo as early therapy in Parkinson’s disease. New Trends Clin Pharmacol 8: 279 (Abstract)

    Google Scholar 

  • Rascol O, Brooks D, Brunt ER, Korczyn AD, Poewe WH et al. (1998) Ropinirol in the treatment of early Parkinson’s disease: a 6-month interim report of a 5-year levodopa-controlled study. Mov Disord 13(1): 39–45

    Article  PubMed  CAS  Google Scholar 

  • Rinne UK (1983) New ergot derivatives in the treatment of Parkinson’s disease. In: Calne DB, Horowski R, Mcdonald R, Wutke W (eds) Lisuride and other dopamine agonists. Raven Press, New York, pp 431–442

    Google Scholar 

  • Rinne UK (1987a) Early combination of bromocriptine and levodopa in the treatment of Parkinson’s disease: a 5-year follow-up. Neurology 37: 826–828

    Article  PubMed  CAS  Google Scholar 

  • Rinne UK (1987b) R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson’s disease. J Neural Transm [Suppl] 25: 149–155

    CAS  Google Scholar 

  • Rinne UK (1987c) Dopamine agonists as primary treatment in Parkinson’s disease. Adv Neurol 45: 519–523

    PubMed  CAS  Google Scholar 

  • Rinne UK (1988) Dopamine agonists as primary treatment in Parkinson’s disease. Adv Neurol 45: 519–523

    Google Scholar 

  • Rinne UK (1989a) Early dopamine agonist therapy in Parkinson’s disease. Mov Disord 4[Suppl 1]: S86–S94

    Article  PubMed  Google Scholar 

  • Rinne UK (1989b) Lisuride, a dopamine agonist in the treatment of early Parkinson’s disease. Neurology 39: 336–339

    Article  PubMed  CAS  Google Scholar 

  • Rinne UK (1999) Kombinationstherapie mit Lisurid und L-Dopa in den FrÜhstadien der Parkinson-Krankheit verringert und verzÖgert die Entwicklung motorischer Fluktuationen. Nervenarzt 70[Suppl 1]: S19–S25

    Article  PubMed  Google Scholar 

  • Rinne UK, Bracco F, Chonza C, Dupont E, Gershamik O et al. (1997) Cabergoline in the treatment of early Parkinson’s disease. Neurology 48: 363–368

    Article  PubMed  CAS  Google Scholar 

  • Schneider E (1995) Alpha-Dihydoergocryptin — Pharmakologie und klinische Effekte. In: Deuschl G (Hrsg) Alpha-dihydroergocryptin — ein neuer Dopamin-Agonist. Thieme, Stuttgart New York, S 7–42

    Google Scholar 

  • Schneider E, Fischer PA, Jacobi R, Kolb R (1981) Mortalität beim Parkinson-Syndrom und ihre Beeinflussung durch L-Dopa. Fortschr Neurol Psychiatr 49: 187–194

    Article  PubMed  CAS  Google Scholar 

  • Schneider E, Fischer PA, Jacobi P, Grotz A (1984) Exogenous psychoses in Parkinson syndrome. Frequency and causal conditions. Fortschr Neurol Psychiatr 52: 207–214

    Article  PubMed  CAS  Google Scholar 

  • Sethi KD, O’Brien CF, Hammerstad JP, Adler CH, Davis TL, Taylor RL et al. (1998) Ropinirole for the treatment of early Parkinson’s disease. Arch Neurol 55: 1211–1216

    Article  PubMed  CAS  Google Scholar 

  • Shannon KM, Benett JP, Friedman JH, for the Pramipexole Study Group (1997) Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. Neurology 49: 724–728

    Article  PubMed  CAS  Google Scholar 

  • Stammler A, Vielhaber K (1972) Die Behandlung des Parkinsonsyndroms mit Dopa in Kombination mit einem Decarboxylasehemmer. Fortschr Neurol Psychiatr 40: 564–568

    CAS  Google Scholar 

  • Steiger MJ, El-Debus T, Andersson T, Findley LJ, Marsden CD (1996) Double-blind study of the activity and tolerability of cabergolin versus placebo in parkinsonians with motor fluctuations. J Neurol 243: 68–72

    Article  PubMed  CAS  Google Scholar 

  • Suchy I, Horowski R (1984) Use of ergot derivative lisuride in Parkinson’s disease. Adv Neurol 40: 515–521

    PubMed  CAS  Google Scholar 

  • Walters JW (1987) D1-dopamine receptor activation required for postsynaptic expression on D2-agonists effects. Science 236: 719–722

    Article  PubMed  CAS  Google Scholar 

  • Watts RL (1997) The role of dopamine agonists in early Parkinson’s disease. Neurology 49[Suppl 1]: 34–48

    Article  Google Scholar 

  • Weiner WJ, Factor SA, Sanchez Ramos JR, Singer C, Sheldon C, Cornelius L, Ingenito A (1993) Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson’s disease [see comments]. Neurology 43: 21–27

    Article  PubMed  CAS  Google Scholar 

  • Wolters E, Tissingh G, Bergmans PLM, Kuiper MA (1995) Dopamine agonists in Parkinson’s disease. Neurology 45[Suppl 3]: S28–S34

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. W. Kuhn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinische Neurochemie, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Würzburg, Bundesrepublik Deutschland

    Peter Riederer

  2. Bezirkskrankenhaus Gabersee, Wasserburg/Inn, Bundesrepublik Deutschland

    Gerd Laux

  3. Wien, Österreich

    Walter Pöldinger

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag Wien

About this chapter

Cite this chapter

Kuhn, W., Müller, T. (1999). Klinik — orale Medikation. In: Riederer, P., Laux, G., Pöldinger, W. (eds) Neuro-Psychopharmaka Ein Therapie-Handbuch. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6400-6_29

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-6400-6_29

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-7315-2

  • Online ISBN: 978-3-7091-6400-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation